Icosapent Ethyl
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Icosapent Ethyl: From Unspecified Original Indication to Hemoglobinopathy
One-Sentence Summary
Icosapent ethyl is a highly purified EPA ethyl ester omega-3 fatty acid; its original approved indication is not recorded in this evidence pack, and the drug is currently not marketed under any tracked license. The TxGNN model predicts it may be effective for Hemoglobinopathy, but this direction is currently supported only by 0 clinical trials and 1 preclinical publication — and that publication studies a different, structurally related compound (epeleuton), not icosapent ethyl itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no license data, original_indications field empty) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 99.09% |
| Evidence Level | L4 |
| Taiwan Market Status | Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for icosapent ethyl is not available in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge embedded in the supporting literature, icosapent ethyl belongs to the class of highly purified eicosapentaenoic acid (EPA) derivatives, which are known to exert antioxidant and anti-inflammatory effects, in addition to their established triglyceride-lowering activity.
The single supporting publication does not study icosapent ethyl directly. It reports that epeleuton, a novel synthetic ω-3 fatty acid structurally related to EPA, reduced hypoxia/reperfusion-driven inflammatory vasculopathy in a mouse model of sickle cell disease — one specific hemoglobinopathy. The rationale is therefore a class-level, mechanistic hypothesis: if EPA-derived compounds can dampen the inflammatory vaso-occlusive cascade in sickle cell disease, a related EPA ethyl ester might theoretically show similar effects. This has not been tested for icosapent ethyl itself, so the link should be treated as exploratory rather than established.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38105727 | 2024 | Preclinical (animal model) | Haematologica | Epeleuton, a synthetic ω-3 fatty acid structurally related to EPA/icosapent ethyl (not the same compound), reduced hypoxia/reperfusion-induced inflammatory vasculopathy in a mouse model of sickle cell disease, suggesting a possible class-level anti-inflammatory mechanism relevant to hemoglobinopathies. |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: The only supporting evidence is a single preclinical study of a different (structurally related) compound in a mouse model — there is no icosapent-ethyl-specific data, no clinical trial, and no established mechanistic pathway confirmed for this drug in hemoglobinopathy. This is a knowledge-graph-driven hypothesis, not an actionable clinical signal.
To proceed, the following is needed:
- TFDA product label / warnings and contraindications data (currently a Blocking data gap — needed before any S1 safety screening can occur)
- Confirmed DrugBank mechanism-of-action data for icosapent ethyl
- Icosapent-ethyl-specific preclinical studies in a hemoglobinopathy model (current evidence is for epeleuton, a different molecule)
- Clarification of the drug’s original approved indication and current regulatory/marketing status, since no license record currently exists in this dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.